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PRENATAL IODINE SUPPLEMENTATION AND NEUROCOGNITIVE 
OUTCOMES IN MILD-MODERATELY DEFICIENT POPULATIONS  
ALICIA HANAU  
ABSTRACT 
 
 Over the past 100 years, there has been significant progress in limiting the 
development of iodine deficiency disorders globally. The recognition that congenital 
cretinism can be eradicated through early iodine supplementation along with the 
implementation of salt iodination in many countries has substantially decreased the 
prevalence of severe iodine deficiency. Yet, there are still populations that are mildly 
iodine deficient, likely due to lack of mandated iodine supplementation programs.  
 While some countries are qualified as iodine sufficient based upon the general 
population’s median urinary iodine concentration, the sub-population of pregnant women 
may be mildly to moderately iodine deficient. Thyroid hormone demand increases during 
gestation to support fetal thyroid function and neurodevelopment. Pregnant women 
require increased iodine intake during pregnancy to account for this increased demand 
and to make up for increased renal iodide losses. The American and European Thyroid 
Associations both recommend that pregnant women in mild to moderately deficient 
populations take a daily 150mcg iodine supplement while planning a pregnancy, 
pregnant, and lactating.  
Studies into the impact of mild to moderate iodine deficiency in pregnancy on 






found that iodine sufficiency or supplementation in pregnancy is associated with higher 
intelligence quotient scores in offspring. Others have found no significant effect of iodine 
sufficiency and iodine supplementation on developmental outcomes.  
 This proposal is a double-blind, placebo-controlled, randomized study evaluating 
the effect of iodine supplementation in pregnancy on long-term neurocognitive outcomes 
of offspring. The study will be implemented in the mildly iodine deficient population of 
Southern England. Results from this study will contribute to and likely expand upon the 
current body of literature. They will also bolster current recommendations for iodine 
supplementation in pregnancy. In addition, this study may have important public health 
consequences including discussions around mandatory salt iodization in mild to 
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CHAPTER 1: INTRODUCTION 
Background 
 
 Iodine is a trace element essential to the production of thyroid hormone. 
Sufficient iodine intake is particularly important during pregnancy as thyroid hormone 
plays a vital role in fetal growth and neurodevelopment.  During early gestation, the fetus 
depends on maternal thyroid hormone delivered through the placenta.  After fetal thyroid 
gland development at 18-20 weeks’ gestation, iodine is transported from mother to fetus 
via the placenta.1 With increased demand for thyroid hormone production, fetal iodine 
need, and increased renal clearance of iodine, there is an increased iodine requirement 
during pregnancy. Iodine deficiency in gestation can result in a range of serious 
neurological and developmental outcomes, described as the iodine deficiency disorders 
(IDDs). Iodine deficiency is recognized as the leading cause of preventable mental 
disability in childhood. One study reported that intelligence quotient (IQ) in children 
living in iodine deficient areas may be up to 13.5 points lower on average than that of 
children in  iodine sufficient areas.2  
Statement of the Problem 
 While the global prevalence of severe iodine deficiency has substantially 
decreased subsequent to global salt iodination efforts since the 1990s, mild to moderate 
iodine deficiency is persistent in many developed countries.1,2  This is especially 
important for pregnant women and their offspring. Inadequate iodine intake can lead to 
adverse outcomes associated with maternofetal hypothyroidism with studies having 
consistently shown that iodine supplementation leads to decreases in maternal and fetal 
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thyroid volume and thyroglobulin.3 However, data regarding the impact of mild iodine 
deficiency in pregnancy on long term neurocognitive outcomes has shown varied results. 
Some observational studies have found an association between adequate urinary iodine 
concentration (UIC) in pregnant women and higher cognitive assessment scores as 
compared to offspring of mothers with mild iodine deficiency.4,5 However, other studies 
have found no significant association, making the importance of iodine supplementation 
in pregnancy an area of controversy.6,7  
This discordance in findings along with the lack of standardized, widespread 
iodine supplementation necessitates further research into the link between mild to 
moderate iodine deficiency in pregnancy and adverse neurocognitive outcomes. The 
American Thyroid Association and European Thyroid Association both recommend 
iodine supplementation in pregnancy in areas of mild to moderate deficiency.3,8  High 
quality evidence could bolster these recommendations, thereby contributing to more 
widespread supplementation. Furthermore, evidence showing an association between 
iodine supplementation and neurocognitive outcomes may encourage public health policy 




In a population of mild to moderate iodine deficiency, offspring of iodine supplemented 
pregnancies will have a significantly higher mean IQ score on the Wechsler Intelligence 




Objectives and Specific Aims 
This study will investigate the long-term effect of prenatal iodine supplementation, in a 
population of mild to moderate iodine deficiency, on neurocognitive outcomes in 
offspring. Specifically, this study aims to:  
 
• Determine the difference between WISC scores in children of iodine 
supplemented versus non-supplemented pregnancies in an appropriate population 
of mild to moderate iodine deficiency  
• Quantify differences in UIC and thyroid function biomarkers between groups of 
supplemented versus non-supplemented pregnancies  
• Quantify differences between Bayley Scale of Infant Development (BSID-III) 





CHAPTER 2: REVIEW OF THE LITERATURE 
 
Overview of Research Topic 
 
Iodine: Nutritional Obtainment, Population Measurement and Physiology 
 
 Iodine, a trace element found in the earth’s crust and leached into soil and water, 
is an essential component of thyroid hormone.1  Iodine can be obtained through various 
food sources although content varies depending on iodine availability in the soil and 
water where foods are grown.  Seafood is thought to be more iodine-rich, as are dairy 
products secondary to iodophor cleansing used by the dairy industry. Iodine may also be 
found in breads where iodate is used as a dough conditioner. Iodine is unevenly dispersed 
in soil and water, leaving many regions naturally deficient of iodine secondary to 
flooding, erosion and glaciations.1 Areas of iodine insufficiency may see the development 
of iodine deficiency disorders (IDDs) in children. The IDDs are a range of diseases that, 
depending on the severity of iodine deficiency, may result in the development of goiter 
(thyroid enlargement), hypothyroidism, stunted growth and developmental delay in 
children.1,2 Developmental delay secondary to iodine deficiency may be profound; 
compared with iodine sufficient populations, populations living in areas of severe iodine 
deficiency may have an IQ of up to 13.5 points lower.2 To prevent the adverse outcomes 
of severe iodine deficiency, the iodination of salt has been employed as a common, safe 
and economical means of providing populations with nutritional iodine.2  
In the early 1900s, the recognition that goiter formation could be prevented with 
iodine supplementation prompted the policy of iodinating salt, which was first 
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implemented in the US and Switzerland in the 1920s.1 In 1993, drawing on the global 
goal to eliminate iodine deficiency as outlined by the World Health Assembly, World 
Summit for Children at the United Nations and the International Conference on Nutrition, 
the WHO and United Nations International Children’s Emergency Fund promoted 
universal salt iodination as the main strategy to eliminate the IDDs.2  In 2018, salt 
iodination remains the primary strategy to eliminate the IDDs and establish global iodine 
sufficiency. As of 2012, it was estimated that around 70% of all households worldwide 
had access to iodized salt.9 Yet, many countries still lack salt iodination programs, which 
has potentially enabled the development of insufficient population iodine status in parts 
of Europe, the Middle East, Africa, South America and North America.2 
 There are a variety of methods to assess iodine status in a population. Thyroid 
function biomarkers, generally obtained through whole or blood spot assays, can 
indirectly reflect iodine status. Thyroglobulin, a protein produced by the thyroid gland, is 
overproduced with both excessive and insufficient iodine intake. While this biomarker 
can reflect population changes in iodine status, the presence of anti-thyroglobulin 
antibodies make it unreliable.10 Enlarged goiter may also reveal iodine insufficiency, 
however, goiter measurement relies on a skilled examiner’s palpation, making it 
insensitive, non-specific and difficult to obtain in a large sample size.1 By far, the most 
commonly used method to gauge iodine status at a population level is through urinary 
iodine concentration (UIC), expressed either in micrograms per volume of urine or as 
micrograms per gram of creatinine. The UIC reflects recent iodine intake as 90% of 
iodine absorbed in the stomach and duodenum is excreted in the urine over the course of 
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24-48 hours.1 UIC varies from day to day making it a poor marker of individual iodine 
status but an adequate marker for population iodine status in a large sample.11  
 
Table 1. Iodine nutrition status in the adult, non-pregnant and pregnant populations by 
median UIC as outlined by the WHO12 
Status Adult, non-pregnant 
Median UIC (μg/L) 
Pregnant 
Median UIC (μg/L) 
Excessive iodine intake >300  >500 
More than adequate 200-299  259-499  
Adequate 100-199  150 - 249 
Mild iodine deficiency 50-99  
<150 (Insufficient) Moderate iodine deficiency 20-49  
Severe iodine deficiency <20  
 
Pregnant women are a unique population when it comes to the assessment of 
iodine status. Both the recommended mean UIC and recommended daily iodine intake 
are higher for pregnant women than they are for any other age group (Table 1). The 
WHO recommends 150mcg of iodine intake per day for non-pregnant adults but 
recommends 220-250mcg per day in pregnant women.12 Despite these increased iodine 
requirements and the higher UIC cutoff for iodine sufficiency during pregnancy, there is 
limited surveillance of population iodine status in pregnant women or women of child-
bearing age. The median UIC in school-aged children has traditionally been used to 
gauge the iodine status of a population. This is problematic because a sufficient median 
UIC in a population’s school aged children may not reflect iodine status in pregnant 
women, who may potentially be iodine deficient.1  
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 Iodine requirements in pregnant women are higher than those recommended for 
adults and children because of an approximately 50% increase in maternal iodine 
requirement.1 The fetal thyroid gland does not fully develop and synthesize thyroid 
hormone until around 20 weeks’ gestation, necessitating an increase in maternal 
production of thyroid hormone to maintain both maternal and fetal euthyroidism.1 
Furthermore, thyroid hormone plays an important role in neuronal migration and brain 
myelination for the growing fetus, making sufficient iodine crucial for adequate 
neurodevelopment in fetal and early postnatal life.1,13 Severely impaired thyroid hormone 
availability during these critical periods may induce irreversible brain damage with 
mental retardation and neurological abnormalities as described by the IDDs.  
There are several physiologic mechanisms that generate increased thyroid 
hormone to meet the increased demand in pregnancy. Human chorionic gonadotropin 
(hCG), the hormone produced by trophoblasts in early pregnancy and by placenta in late 
pregnancy, is structurally related to thyroid stimulating hormone (TSH), which stimulates 
thyroid hormone production by the thyroid gland. hCG has a weak stimulatory effect on 
the thyroid gland to increase thyroid hormone production. Beginning in early and peaking 
at mid-gestation, elevated estrogen levels result in increased thyroid-binding globulin 
levels (TBG), expanding the thyroid hormone binding capacity of the serum.14 
Mechanisms that increase thyroid hormone production and availability are 
accompanied by losses of iodine and thyroxine (T4) in pregnancy.  In early gestation, 
increased glomerular filtration leads to increased renal iodide clearance. The placenta has 
type 3 deiodinases, enzymes which convert T4 into reverse triiodothyronine (T3), an 
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inactive form of thyroid hormone. Meeting adequate iodine demand for increased thyroid 
hormone production is necessary to support fetal neurodevelopment especially in the 
setting of increased iodine losses in the urine.14 
 
Effects of Iodine Deficiency in Pregnancy on Offspring Neurodevelopment  
 
Cretinism, one of the most severe forms of the IDDs, may develop in populations 
with severe and chronic iodine deficiency. While variable, common characteristics of 
cretinism include neuro-motor defects, short stature, severe mental retardation, deaf 
mutism, and motor spasticity. Mental deficits are characterized by impaired abstract 
thought with preserved autonomic, vegetative and memory function.1 Five breakthrough 
RCTs published in the 1980s, each performed in severely iodine deficient areas, showed 
that iodine supplementation in early pregnancy can markedly reduce, if not eradicate, 
endemic cretinism.1 One of these studies, performed from 1966 through 1972, alternated 
giving injections of saline or iodized oil to families living in a severely iodine deficient 
area of Papua New Guinea.15 Iodine supplementation was associated with a significant 
reduction in the prevalence of endemic cretinism. Of 274 children born into the iodine 
supplemented group, three were definite cretins (all three mothers had received iodinated 
oil injection after their conception) and three were possible cretins. Of the 248 children in 
the saline injection group, 16 were definite cretins and 11 were possible cretins with 
significant differences between groups (p <0.001).15 This study along with others of 
similar design in severely iodine deficient areas found that endemic cretinism is 
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preventable through the administration of supplementary iodine to mothers before 
conception.16  
While the effects of severe iodine deficiency on offspring are well understood, the 
impact of gestational mild to moderate iodine deficiency on offspring are more uncertain. 
Some influential prospective cohort studies have found associations between mild to 
moderate iodine deficiency in pregnancy and adverse neurocognitive outcomes. One such 
study investigated a subsample of pregnant women from the Avon Longitudinal Study of 
Parents and Children (ALSPAC) cohort based on the availability of urine samples. The 
total subsample of 958 pregnant women was divided into two groups, iodine insufficient 
and iodine adequate. Subjects with a UIC <150mcg/L were placed in the iodine 
insufficient group (n=646) and subjects with a UIC >150mcg/L were placed in the iodine 
adequate group (n=312). The major outcomes measured were offspring’s IQ at 8 years of 
age using the abbreviated Wechsler Intelligence Scale for Children (WISC) and reading 
speed, accuracy and comprehension at 9 years old using the Neale Analysis of reading 
ability. After adjusting for confounders, the study found statistically significant 
differences between the two groups in verbal IQ (p=0.002), reading accuracy (p=0.001), 
and reading comprehension (p=0.007) favoring the iodine sufficient group. Additional 
analyses found that the offspring of women with a UIC <150mcg/L in early pregnancy 
had increased odds of having an IQ in the lowest quartile (score of less than 85) 
compared to the iodine sufficient group (p=0.03).4 Another prospective cohort study 
performed in Tasmania between 1999 and 2001 compared long-term cognitive outcomes 
in offspring of iodine sufficient versus insufficient pregnancies. This study similarly 
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divided its cohort of 228 pregnant women into an iodine inadequate group (UIC 
<150mcg/L, n=162) and an iodine adequate group (UIC >150, n=66). At 9 years of age, 
offspring of these pregnancies took two standardized tests which cumulatively measured 
students’ performance in literacy, language, numeracy, speaking, listening, reading, 
viewing, writing and mathematics. There were statistically significant differences in 
spelling (p=0.003), grammar (p=0.038) and English literacy (p=0.034), representing a 
10%, 7.6% and 5.7% reduction respectively in the iodine insufficient group.5  
Strengths of these studies include their measured outcomes, population 
characteristics and adjustments for confounders. Both studies evaluated elementary 
school-aged children. As will be seen throughout this thesis, many studies employ 
assessments such as the Bayley Scales of Infant Development (BSID-III) at 1 to 42 
months old to measure neurocognitive outcomes. Measuring IQ in older children as was 
done in these studies is arguably more valuable; cognitive assessment at a young age may 
be less predictive of long-term intelligence than tests administered to school-aged 
children.17  These studies also sampled uniquely appropriate populations. Southwest 
England is an ideal location for this type of study because the UK has seen the one of the 
most drastic resurgences of mild-moderate iodine deficiency in Europe.1 In the Tasmania 
study, women were recruited between 1999 and 2001, a time of documented mild iodine 
deficiency just prior to the initiation of voluntary iodine fortification in 2001. Therefore, 
in this cohort, gestation took place at a time of iodine deficiency while offspring were 
reared in an iodine replete environment. This opportune timing helped to control for 
iodine deficiency in childhood as a potential cause for differences in test scores. Finally, 
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these studies were highly powered to detect statistically significant differences between 
groups at an alpha of 0.05. Each study also adjusted for a number of potential 
socioeconomic, nutritional and maternofetal health confounders that could impact the 
cognitive development of offspring.  
Unlike the studies discussed above, some studies with similar designs and 
subjects did not find an association between mild-moderate iodine deficiency in 
pregnancy and negative neurocognitive outcomes. A Dutch study testing non-verbal IQ 
and language comprehension in six-year-old children found no association between low 
maternal UIC in pregnancy and IQ after adjusting for confounding factors.6 A cohort 
study in three different mildly-moderately iodine deficient regions of Spain used the 
Bayley Scales of Infant Development to assess mental and psychomotor development in 
offspring at around 16 months old. In addition to measuring maternal UIC, this study 
measured maternal iodized salt consumption and dietary iodine intake through 
questionnaires. In one region, offspring of mothers who reported taking a dose of 150mcg 
or more of iodine daily had significantly lower BSID-III psychomotor scores (mean = 
93.3) than children of mothers who took 100-149 mcg/day (mean = 100.5) and less than 
100 mcg/day (mean = 98.2).19 This finding suggests a potential increased risk with 
increased iodine supplementation. However, this cohort study did not find an association 
between low maternal UIC and adverse neuropsychological outcomes in offspring.7  
 
Current Solutions and Recommendations 
 
The neurocognitive outcomes of severe iodine deficiency in pregnancy and modes 
of prevention are well established. Through global efforts since the 1990s, programs of 
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universal salt iodination have greatly improved iodine access worldwide. Global 
assessment of iodine status in 2013 showed that of those countries studied, 10 had excess 
iodine, 111 had adequate iodine nutrition, 21 had mild iodine deficiency and 9 had 
moderate iodine deficiency based on the UIC of school-aged children The number of 
iodine adequate countries increased from 67 in 2003 to 111 in 2013, showing great 
improvement over the course of those 10 years.18  
Still, mild to moderate iodine deficiency has recently been recognized as a public 
health issue in some developed countries. While this may be marginally affected by 
country-specific factors including changes in diet, this phenomenon is most likely 
secondary to the lack of mandatory salt iodination in places like the USA and even 
voluntary salt iodization in parts of Europe. A 2013 questionnaire deployed by the 
International Council for Control of the Iodine Deficiency Disorders (ICCIDD) in 
Western and Central Europe found that 21 of 35 countries lack mandatory salt iodization. 
This represents up to 400 million people living in Europe with limited access to iodized 
salt.19 It is also worth reiterating that while some countries have overall satisfactory 
iodine status based on their population of school-aged children, this is often a poor 
barometer of iodine status in pregnancy given the higher dairy content in children’s diets 
and the increased iodine requirement in pregnancy.1,19  
The need to elucidate the impact of iodine supplementation in pregnant women 
living in mild to moderately iodine deficient areas on long-term neurocognitive outcomes 
is especially timely. While the findings of the observational studies discussed above are 
suggestive of important consequences, evidence is lacking as to the efficacy of iodine 
 
13 
supplementation in pregnancy on offspring’s neurodevelopmental outcomes. 
Furthermore, the cohort studies discussed above are not interventional in design and, 
therefore, do not comment directly on the American and European Thyroid Associations’ 
recommendations for iodine supplementation. Both associations recommend that 
pregnant women supplement their diets with 150 mcg daily iodine while planning a 
pregnancy, pregnant, and lactating.3,8  
Interventional studies investigating the effects of iodine supplementation in 
pregnancy in moderate-mild iodine deficient populations are needed to bolster these 
public health recommendations. Furthermore, well-powered, well-designed interventional 
studies can inform public health initiatives centered around salt iodization programs, 
which may also provide economic value. Reduced IQ and school performance can 
negatively affect a population’s economy and productivity.20 Small decreases in IQ are 
associated with lower income with one study estimating that an increase by 1 IQ point 
yields a 3.631% gain in earnings.21 Salt iodination is also cost effective.  In 2014, the 
WHO estimated that, if the cost of iodized salt is $0.10 per person per year, the benefit–
cost ratio is 26.5:1 and even higher in Central America, where the cost of salt iodization 
is $0.01 per person per year.22 
 
Synthesis of Existing Research 
 
Summary of Existing Interventional Study Data  
 
Thus far, there have only been a handful of interventional studies exploring iodine 
supplementation in pregnancy in mild to moderate iodine deficient areas.  Most of these 
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studies focus on changes in maternal and fetal thyroid function, volumes and UIC but few 
have examined long-term developmental consequences in the offspring. Seven 
randomized control trials (RCTs) performed in Europe, in areas of mild to moderate 
iodine deficiency with median population UICs of 36-109 mcg/L, randomized pregnant 
women to either an interventional arm (receiving iodine supplementation ranging from 
50-300 mcg/day) or to a control arm (receiving either no iodine supplement, a lower daily 
dose than the interventional group or iodized salt alone).  The results of these studies are 
beyond the scope of this paper as they do not comment on long-term neurocognitive 
outcomes directly. In brief, a meta-analysis of these seven studies shows a rise in 
maternal UIC in groups supplemented with iodine compared to untreated controls. Five 
of these RCTs also compared maternal TSH in supplemented versus non-supplemented 
groups. Three of these five studies found a rise in TSH in untreated controls compared to 
supplemented groups. In the four studies that evaluated thyroid peroxidase (TPO) 
antibody status, women in both interventional and control groups were more likely to 
develop post-partum thyroid dysfunction if they were TPO antibody positive; this 
outcome was not affected by iodine supplementation. Results of iodine supplementation 
on free thyroxine (FT4) levels were more discordant among the trials.20  
Recent trials have explored the long-term neurocognitive effects of iodine 
supplementation in pregnancy. As a whole, this group of studies have some limitations 
and faced ethical challenges.  Some interventional studies were not randomized and some 
were not adequately powered. Some RCTs, while strong in their design and statistical 
analysis, had poor population selection. In addition to these technical challenges, this 
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group of studies faced ethical issues. Where iodine supplementation is recommended, 
even without mandated iodization programs, it could be considered unethical to withhold 
iodine supplementation making it challenging to designate a placebo arm.  
Five of the studies that explore the neurocognitive outcomes of iodine 
supplementation in pregnant women of mild to moderate iodine deficiency will be 




             Table 2: Basic design and results of five controlled trials examining the effect of iodine supplementation in pregnancy  
             on offspring neurocognitive outcomes. 
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In-Depth Descriptions and Critiques of 5 Interventional Studies:  
 
 
Study 1: Velasco I, Carreira M, Santiago P, et al. Effect of iodine prophylaxis during 
pregnancy on neurocognitive development of children during the first two years of life. J 
Clinical Endocrinology and Metabolism. 2009;94(9):3234-4123 
 
This was a non-randomized control trial published in 2009 that took place in 
Andalusia, Southern Spain. The overall sample size was 194 pregnant women. The 
interventional group consisted of 133 women, recruited consecutively, who were given a 
daily 300 mcg potassium iodide supplement from the first trimester until the end of 
pregnancy. Sixty-one women who presented in the last month of their pregnancy and had 
not taken any iodine supplements were selected as control subjects.   
The main exposure variable was iodine supplementation. Other explanatory 
variables were measures of thyroid function, UIC, and demographic and clinical 
characteristics. In the experimental group, maternal UIC, TSH, FT4, free triiodothyronine 
(FT3), and thyroglobulin were measured at baseline and in each trimester. The same 
explanatory variables, except for thyroglobulin, were measured in the control group in the 
third trimester. Following parturition, maternal milk iodine content along with cord blood 
TSH and neonatal UIC were measured in both groups. Additional explanatory variables 
measured in all subjects were maternal and paternal age and education level, offspring 
sex, birthweight, length of gestation, APGAR score at 5 and 10 minutes, prematurity, and 
the presence of lactation and siblings. The primary outcome measure was the BSID-III, 
which has three components contributing to final score -- the Mental Developmental 
Index (MDI), the Psychomotor Developmental Index (PDI) and the Behavior Rating 
Scale (BRS).  
 
18 
The supplemented group had a significantly higher mean UIC at 263.04±120.75 
mcg/L than the control group in the third trimester at 87.61±62.06 mcg/L (p<0.001), as 
did supplemented infants versus control infants (p=0.002). Maternal TSH, FT4 and FT3 
levels were all significantly lower in the supplemented group than in the control group 
(p≤0.001). Cord blood TSH was higher in the supplemented group at 7.93±5.06 mIU/ml 
than in the control group at 3.77±2.81 mIU/ml (p<0.001). The content of iodine in breast 
milk was significantly higher in the supplemented group (p=0.005). There were no 
significant differences between groups in demographic and clinical characteristics, except 
in length of pregnancy and mean age of BSID-III administration. Length of pregnancy in 
the supplemented group was 38.90±2.04 weeks and in the control group was 40.27±1.33 
weeks (p<0.001). BSID-III administration was at 5.47±2.86 months of age in the 
supplemented group and 12.44±4.96 months of age in the control group (p<0.001).  
The outcomes of this study did not show a statistically significant difference in 
mean MDI scores between the supplemented and control groups (109.22±11.73 and 
108.90±13.41 respectively, p>0.05). The mean PDI was around 6 points higher in the 
supplemented group than the control group (108.74±13.74 versus 102.65±14.60, p=0.02), 
representing a 5.9% increase. In subsequent ANOVA modeling, lactation was a 
confounding variable in the variance of the PDI scores and the PDI correlated 
significantly with umbilical cord TSH. There were also statistically significant 
differences in items on the Behavior Rating Scale between groups, such as reaction to 
persons (p=0.02), cooperation (0.008), activity (p=0.01) and arousal (p=0.04), favoring 
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the iodine supplemented group after adjusting for weeks of gestation, prematurity and 
sex.   
The difference in PDI test scores between groups was clinically meaningful. 
While both the experimental and control groups scored above the average score (100) on 
the MDI and PDI, the average PDI score in the control group is about the 50th percentile, 
while the PDI score in the supplemented group is about the 72nd percentile.24 This 
difference in percentiles represents a clinically meaningful outcome despite a mean 
increase of only 5.9%. 
One strength of this study lies in its population selection.  At this time, only 30% 
of the population in this region of Spain was reported to consume iodized salt and the 
mean UIC concentration of pregnant women in this area was <100 mcg/L.27 The control 
group had a mean UIC consistent with moderate iodine deficiency at  87.61±62.0 mcg/L 
in the third trimester, while the intervention group had third trimester mean UIC 
consistent with more-than-adequate iodine sufficiency at >150mcg/L in all three 
trimesters and at 263.04±120.75 mcg/L in the third trimester (p <0.001). The control 
subjects’ mildly iodine deficient status make the results of this study generalizable to 
other areas of moderate iodine deficiency.  
This study’s strengths are accompanied by limitations that pertain to its design, 
control group selection, sample size and confounding factors. First, while interventional 
studies can indicate a relationship between an intervention and a specified outcome, this 
study was non-randomized with recruitment of control and interventional groups at 
different points in pregnancy, which can result in selection bias. It is, therefore, possible 
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that the conclusions of this study are the result of inherent differences between the two 
groups. More specifically, while the control group selection was ethically responsible in 
that iodine supplementation was not actively withheld from any participants, the subjects 
only presented at the end of their third trimester. While the adequacy of the control 
subjects’ prenatal care prior to presentation is unknown, the subjects’ late presentation in 
pregnancy may represent inadequate prenatal care in some subjects that may not have 
been accounted for in the secondary explanatory variables. There is, therefore, the 
potential for residual confounding in the neurodevelopmental outcomes test results. The 
late presentation of the control subjects is also problematic because there is no 
information on maternal thyroid function and UIC from early pregnancy in the control 
group, making it impossible to account for baseline differences between groups. The 
overall sample size is also quite small at less than 200 subjects. Finally, the average ages 
of BSID-III administration were significantly different -- 12.44±4.96 months and 
5.47±2.86 months (p=<0.001) in control and interventional groups, respectively. The 
BSID-III does correct for differences in age at test administration by creating an index 












Study 2: Berbel P, Mestre JL, Santamaría A, et al. Delayed neurobehavioral development 
in children born to pregnant women with mild hypothyroxinemia during the first month 
of gestation: the importance of early iodine supplementation. Thyroid. 2009;19(5):511-
9.25 
 
This was a non-randomized control trial published in 2009 that took place in 
Alicante, Spain. The overall initial sample size was 345 pregnant women. Three groups 
were enrolled in this study: Group 1 at 4-6 weeks gestation (n=92), Group 2 at 12-14 
weeks (n=102), and Group 3 at 37-40 weeks (n=151). All groups were supplemented 
with daily 200 mcg potassium iodine per day from the enrollment period through the end 
of lactation. 
The main exposure variable was iodine supplementation. Other explanatory 
variables were UIC, TSH and FT4 measured at enrollment and at term in each group. To 
obtain homogenous groups of offspring for neurodevelopmental evaluation, a lengthy set 
of pre- and postnatal epidemiological and socio-cultural exclusion criteria were applied to 
the three study groups. Prenatal exclusion criteria included maternal weight increase of 
greater than 15kg, alcohol use during pregnancy, smoking more than 10 cigarettes per 
week, single parent family, school education less than 14 years, unemployment and rural 
home. Postnatal exclusion criteria included caesarean section, APGAR less than 6 at five 
minutes, abnormal infant birth weight, height and head circumference, severe disease or 
malformation, lactation of less than six months, reduction in hearing ability and poor 
parental care. In addition to these exclusion criteria, children were only evaluated if their 
mothers met specific inclusion criteria. Children from Group 1 were evaluated if their 
mother had a normal TSH and a FT4 above the 20th percentile both at enrollment and at 
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full term. Children from Group 2 were evaluated if they were born to mothers who had 
mild hypothyroxinemia (normal TSH and low T4) in the first trimester with a normalized 
free T4 above the 20th percentile at term. Children from Group 3 were evaluated if they 
were born to mothers who had mild hypothyroxinemia at term. This left a total of 44 final 
study subjects, 13 in Group 1, 12 in Group 2, and 19 in Group 3. The primary outcome 
assessment was the Brunet-Lezine score, which evaluates gross and fine motor 
coordination, language skills and socialization of offspring at 18 months.   
At term, mean UIC was found to be higher in groups 1 (120.5±41.7mcg/L) and 2 
(96.7±39.9mcg/L) compared to group 3 (74.6±0.8mcg/L, p<0.001). Group 3 had the 
highest percentage of women with low FT4 (within the 10th-20th percentile) at 21.2% 
versus 4.4% and 14.3% in Groups 1 and 2, respectively. FT4 was also significantly 
higher in Group 1 (1.03±0.04ng/dL) and Group 2 (1.02±0.11ng/dL) at term than in Group 
3 (0.77±0.04ng/dL, p<0.001). On the Brunet-Lezine scale, the mean developmental 
quotient in Group 1 (101.8±9.7) was significantly higher than in Groups 2 (92.2±15.4; 
p<0.05) and 3 (87.5±8.9; p<0.001) without statistically significant differences between 
Groups 2 and 3 (p=0.49). Children with delayed performance were only observed in 
Groups 2 (25%) and 3 (36.8%). Statistically significant differences were found between 
groups in gross and fine motor coordination and socialization scales with Group 1 
children obtaining the highest quotients (p<0.001). These results suggest that delaying 
maternal iodine supplementation increases the risk of developmental delay in offspring. 
 This study’s greatest strength lies in its sample specifications and recruitment 
periods, which enabled the comparison of groups supplemented at specific periods in 
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pregnancy. The results suggest that iodine supplementation in the first trimester of 
pregnancy (4-6 weeks) is most beneficial. Furthermore, results of this study suggest that 
supplementation beyond 12-14 weeks was not associated with neurodevelopmental 
benefit. By definition, Group 2 had hypothyroxinemia at 12-14 weeks with resolution at 
term and Group 3 had mild hypothyroxinemia at term. Despite resolution of 
hypothyroxinemia in Group 2, likely because of iodine supplementation, there was still 
no statistically significant difference between Groups 2 and 3 on the Brunet-Lezine scale 
(p=0.49). An additional strength of this study was in its population selection. This study 
also found that 33% of the original sample of 345 pregnant women had low FT4 levels 
(hypothyroxenemic), indicating the high prevalence of iodine insufficiency in this region. 
This makes the population selection appropriate and generalizable to other mild to 
moderately deficient populations. Furthermore, this study employed TSH and FT4 to 
assess thyroid function, a marker of individual thyroid disease and/or iodine sufficiency, 
rather than only using UIC.  
This study’s application of strict inclusion and exclusion criteria was somewhat 
problematic. On the one hand, the strict criteria enabled the comparison of 
supplementation at different time points in pregnancy and also standardized the final 
study population so that subjects had comparable health and social environments. On the 
other hand, the specific assignments of participants to study groups epitomizes allocation 
bias and subject recruitment at different times may have led to residual confounding in 
the results. The lengthy set of inclusion and exclusion criteria also limited the study’s 
sample size. From an original 345 total subjects, the sample size of evaluated offspring 
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was cut down significantly to a total of 44 subjects (Group 1 n=13, Group 2 n=12, Group 
3 n=19) making it potentially inadequately powered. If inadequately powered, the lack of 
a statistically significant difference between Group 2 and 3 BSID-III scores may have 
been the result of a beta error. The selection of Group 1 was also problematic as these 
women were never mildly hypothyroxinemic. This group may, therefore, not be 
comparable to Groups 2 and 3, both of which were classified by their initial 
hypothyroxinemia.   
 
Study 3: Zhou SJ, Skeaff SA, Ryan P, et al. The effect of iodine supplementation in 
pregnancy on early childhood neurodevelopment and clinical outcomes: results of an 
aborted randomised placebo-controlled trial. Trials. 2015;16:563.26 
 
This study, designed as a randomized, double-blinded, placebo-controlled trial, 
was published in 2015 and took place in Adelaide, Australia. The proposed total sample 
size was 1,084 pregnant women. However, the study was aborted prematurely and had a 
final sample size of only 59 women. Subjects were recruited at less than 20 weeks’ 
gestation and randomly assigned 1:1 to either an interventional or placebo group. The 
interventional group consisted of 29 women who were given a daily 150mcg potassium 
iodide supplement to take from enrollment until the end of pregnancy. The control group 
consisted of 30 women who were given an identical daily placebo tablet to take from 
enrollment through pregnancy.  
 The main exposure variable was iodine supplementation. Secondary explanatory 
variables were maternal UIC, FT3, FT4, TSH and thyroglobulin measured at study entry 
and 36 weeks’ gestation in both the control and interventional group.  At six week 
postpartum, newborn TSH and breast milk iodine were also measured. Additional 
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explanatory variables measured were maternal age, parity, education level, smoking 
status prior to and during pregnancy, prior miscarriages, depression, BMI and infant 
gestational age and sex. The primary outcome measure was the BSID-III at 18 months of 
age.  
When only 59 women had been randomized, the funding body of the study 
withdrew its financial support as the placebo group was considered to be discordant with 
the council’s recommendations for iodine supplementation in pregnancy. The study was 
subsequently un-blinded when subjects were at a mean gestational age of 33±7 weeks 
and subjects were enabled to withdraw from the study and/or discontinue treatment. One 
woman from each group withdrew, 5 women in the experimental group discontinued 
their iodine supplement, and 18 in the control group discontinued their placebo.  
 This study found that the median UIC of the iodine supplemented group increased 
by 87mcg/L from baseline to 36 weeks (p<0.001), while the median UIC of the control 
group did not show a significant change from baseline to 36 weeks (p=0.71). There were 
no statistically significant differences found between the groups’ FT3, FT4 and TSH 
levels at baseline or 36 weeks, nor between cord blood TSH, neonatal TSH, breast milk 
iodine concentration or maternal baseline characteristics. The overall outcome of this 
study was that there was no significant difference between Bayley scale cognitive, 
language and motor development scores between the offspring of the two groups (p=0.42, 
0.83 and 0.61, respectively). 
As originally designed, this study would have had multiple strengths had it been 
fully implemented. This includes the goal to recruit a large sample size with a high power 
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to be able to detect clinically meaningful differences in BSID-III scores.  In prior studies 
using the Bayley scale, four point differences between groups secondary to nutritional 
deficits and environmental exposures have led to initiations of or major changes in health 
campaigns. 26 With its strengths lying in its original design, this study has some obvious 
and drastic limitations because of its premature cessation. Only 59 of the proposed 1,084 
participants were recruited and studied. This small sample size has a low statistical 
power, increasing the chance of committing a type II error. Furthermore, the study was 
un-blinded with some participants stopping treatment, making it difficult to interpret any 
findings and most likely leading to a misclassification bias.  
Even if this study had been carried out fully, there are still some weaknesses in its 
design. First, by the time this study began recruitment in 2010, Australia and New 
Zealand had implemented a mandated iodine fortification of bread.  A more appropriate 
population might be one without a mandated iodine fortification policy, even though the 
mean UIC in this population between 2011 and 2012 was 121 mcg/L.27 An additional 
weakness was the timing of iodine supplementation. Women were eligible for study 
inclusion if they were less than 20 weeks pregnant.  The mean gestational age at entry for 
the iodine supplemented group was 15.2 weeks and 14.9 weeks for the placebo group. 
Both of these starting times are past the first trimester and the limit of 20 weeks for study 
inclusion is well into the second trimester.  As suggested by Study 2 and the significant 
neurodevelopment that occurs early on in pregnancy, the first trimester may be the most 
important and impactful time for supplementation. Therefore, supplementation may not 
have been initiated early enough to impart meaningful change in fetal development.  
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Study 4: Santiago P, Velasco I, Muela JA, et al. Infant neurocognitive development is 
independent of the use of iodised salt or iodine supplements given during pregnancy. Br J 
Nutr. 2013;110(5):831-9.28  
 
This was a randomized controlled trial published in 2013 that took place in Jaen, 
Spain. The overall sample size was 131 pregnant women recruited at less than 10 weeks’ 
gestation. All study participants were instructed to replace home salt with iodized salt and 
were then randomly split into three groups: iodized salt only (n=38), 200mcg of 
potassium iodide per day (n=55) and 300mcg of potassium iodide per day (n=38). 
The primary exposure variable was iodine supplementation. Other explanatory 
variables were UIC, TSH, FT4, FT3, thyroglobulin and thyroid volume, each measured in 
all three trimesters of pregnancy and between 3 and 6 months postpartum. Additional 
explanatory variables were maternal age, length of pregnancy, newborn birthweight, 
APGAR scores, cord blood TSH, newborn thyroid volume and breast milk iodine 
content. The primary outcome measure was the BSID-III between 6 and 18 months of 
age.  
 The mean UIC in all subjects prior to study intervention was 131 mcg/L, 
indicating moderate iodine deficiency, with no significant differences between the three 
groups.  In the third trimester, the 300mcg supplemented group had the highest median 
UIC at 213.4±114.6mcg/L compared to the 200mcg supplemented group at 
166.1±74.6mcg/L and the iodized salt group at 144.2±85.4mcg/L. All three groups saw a 
statistically significant increase in median UIC from the first to the third trimester 
(p=0.001). There was a statistically significant difference in median UIC between all 
three groups, however, there was no statistically significant trimester and treatment group 
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interaction in median UIC (p=0.01 and p=0.15 respectively). TSH increased slightly in 
the third trimester as compared to baseline in all three groups but there was no significant 
difference depending on treatment group. FT4 and FT3 decreased while thyroid volume 
increased significantly during pregnancy in all three groups (p<0.001, p<0.001, and 
p=0.04, respectively), however there was similarly no statistically significant trimester 
and treatment group interaction (p=0.16, p=0.06, and p=0.72, respectively). There were 
no statistically significant changes in thyroglobulin levels across trimesters in each group 
or between groups. There were also no significant differences between other maternal 
and fetal characteristics between groups.  
At a mean age of 12.8 months, a total of 102 children from the three groups (n=25 
for group 1, n= 47 for group 2 and n=30 for group 3) underwent BSID-III testing. After 
adjusting the ANOVA model for gestational age at birth and for infant age at time of 
assessment, there were no statistically significant differences in Bayley-III MDI, PDI or 
total developmental index scores between treatment groups (p>0.05).  
This study’s strengths mirror many of those discussed in regards to other studies. 
The population examined was moderately iodine deficient, therefore making this study 
generalizable. This study was also ethical in its design in that all groups including the 
control were instructed to replace home salt with iodized salt. One issue with the ethical 
design is that it does not enable comparison of final outcome measures in supplemented 
versus non-supplemented pregnancies. All three groups were supplemented with some 
form of iodine beginning in the first trimester and all three groups subsequently saw a 
rise in median UIC from the from first trimester. While the iodized salt group had a 
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median UIC < 150 mcg/L at term, the mean UIC of 144.2±85.4mcg/L hovers around this 
threshold. The other interventional studies discussed earlier found median UICs of 
around 70-80mcg/L in non-supplemented groups in the third trimester. Sufficient iodine 
supplementation in all three groups may account for the lack of statistically significant 
differences in BSID-III scores. An additional limitation of this trial was that it did not 
achieve its goal sample size. To detect a statistically significant difference in PDI on the 
Bayley Scale with a power of 80%, the number of required cases was seventy-eight 
(n=26 per group). While two of the groups had samples with greater than 26 subjects, one 
group only had 25 subjects.  The drawbacks of the variable timing of BSID-III 
assessment also apply to this study, as offspring were tested at a range of six to eighteen 
months.  
 
Study 5:  Gowachirapant S, Jaiswal N, Melse-boonstra A, et al. Effect of iodine 
supplementation in pregnant women on child neurodevelopment: a randomised, double-
blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(11):853-863.17 
 
This was a randomized, double-blind, placebo-controlled trial published in 2017 
that took place at Ramathibodi Hospital of Mahidol University in Bangkok, Thailand, and 
St. Martha’s Hospital in Bangalore, India.  The overall initial sample sizes was 832 
pregnant women (514 from Bangkok and 318 from Bangalore) enrolled in the first 
trimester and randomly assigned 1:1 to either receive 200 mcg of iodine or a placebo pill 
to be taken through the end of pregnancy.  
 The main exposure variable was iodine supplementation. There were multiple 
secondary explanatory variables including UIC, thyroid volume, TSH, thyroglobulin, 
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FT4 and TPO antibodies measured in both groups in all three trimesters and at 6 weeks 
postpartum. Data collection for secondary explanatory variables in the mothers and 
offspring was multi-factorial (Table 3). The co-primary outcome measures were 
Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III) and the Behavior 
Rating Inventory of Executive Function Preschool Version (BRIEF-P) scores collected in 
offspring at four to five years old. 
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At baseline, when calculated by recruitment site, median UIC in the Bangalore 
cohort was > 150mcg/L at 188mcg/L, while the median UIC of the Bangkok cohort was 
< 150 at 112mcg/L. At baseline, when calculated by treatment group, the iodine and 
placebo groups had a mean UIC of less than 150mcg/L at 135mcg/L and 125mcg/L, 
respectively. While the supplemented group had a significantly higher median UIC than 
the placebo group throughout pregnancy, both groups had a median UIC above 
150mcg/L in the second and third trimesters (p<0.0001). The supplemented group had a 
slightly higher FT3 and total T3 than the placebo group at 6 weeks postpartum and also 
lower thyroglobulin levels than the placebo group during pregnancy (p=0.03 and 
p=0.0009, respectively). Otherwise, there were no significant differences in maternal 
thyroid function tests, thyroid volume or TPO antibodies between groups during 
pregnancy and at 6 weeks postpartum. Overall, there was no significant difference in 
frequency of adverse outcome events between groups. This, combined with the minimal 
differences between groups in thyroid function tests, indicates that 200mcg of daily 
iodine supplementation in pregnancy is safe.  
A total of 166 children from the iodine supplemented group and 164 children 
from the placebo group were administered the WPPSI-III and BRIEF-P at a mean of 5.4 
years of age. No significant differences were detected between the groups in age, sex, 
height, weight, thyroid function tests and other characteristics. There were no significant 
differences between groups in WPPSI-III scores with means for verbal IQ at 89.5 and 
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90.2, performance IQ at 97.5 and 99.1 and full-scale IQ at 94.9 and 96.1 in the iodine and 
placebo groups, respectively (p=0.77, p=0.44 and p=0.44).  BREIF-P global executive 
function scores at 5.4 years were 90.6 and 91.5 for the iodine and placebo groups, 
respectively (p=0.74). Similarly, NBAS scores and Bayley III scores were not statistically 
different between groups. 
Many of the weaknesses of the aborted Zhou et al RCT are strengths of this study. 
The study determined that 142 children per group were needed to have an 80% power to 
detect a 5-point difference in WPPSI-III scores. At study completion, 166 children from 
the iodine group and 164 children from the placebo group were assessed, thereby 
surpassing the goal sample size. Most of the primary and secondary outcome assessments 
were carried out at the intended time-points. Only the WPPSI-III, BRIEF-P and SDQ 
were administered late at mean of 5.4 years of age due to delays in locating the children. 
The subjects’ compliance with iodine supplements and placebo was high, measured at 
87% with no significant differences between groups via pill counts (p=0.76). Unlike the 
Zhou et al trial and other interventional studies described here, this study employed 
multiple, distinct methods to assess for neurocognitive outcomes. These assessments 
were varied in content and in their time of administration. Therefore, had there been any 
statistical differences between groups in any category and at any time-point, there would 
have been a clearer understanding of the precise impact of mild iodine deficiency in 
pregnancy on neurocognitive outcomes. Furthermore, testing at a later age (5-6 years old) 
allowed for the assessment of a wider range of categories of cognitive function than the 
Bayley-III and is likely more predictive of long-term neurocognitive outcomes.29 This 
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study also initiated iodine and placebo supplementation in the first trimester at a mean 
gestational age of 10.7 weeks.  
This labor-intensive study was not only very well designed but also meticulously 
followed through on each of its many procedures with few missteps. However, one flaw 
of the study was in its population selection. At baseline, the median UIC of the entire 
study group was 131 mcg/L indicating mild iodine deficiency. The group from Bangkok 
had a median UIC of 121 mcg/L at baseline. However, at baseline, the group from 
Bangalore had a higher median UIC of 188 mcg/L. This indicates that subjects recruited 
from Bangalore were in fact iodine sufficient (UIC >150mcg/L) and would, therefore, 
likely not require nor benefit from supplementation. At the time of study intervention 
(2008-2011), no data was available for iodine status in women of reproductive age in 
Bangalore. A cross-sectional study carried out between May 2008 and September 2011 in 
Bangalore with the aim of assessing iodine intake in Indian pregnant women and their 
children found that the overall median UIC in women was 172mcg/L with the median 
UIC being greater than 150mcg/L in all trimesters.30 
  In this RCT, both the intervention and placebo groups were found to have a 
median UIC >150 mcg/L in the second and third trimesters. This qualifies the placebo 
group as iodine sufficient overall despite the lack of iodine supplementation. 
Furthermore, while the median UIC was higher in the supplemented group than in the 
placebo group, there were no statistically significant differences in UIC between groups 
in the second and third trimesters (p=0.61). The authors of this study suggest that the 
placebo group’s adequate median UIC may be secondary to the subjects’ increased intake 
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of iodine rich foods.17 During enrollment, subjects were told about the importance of 
iodine intake in pregnancy, which may have prompted changes in their diet, ultimately 
biasing the trial results toward a null effect. The authors also suggest that the adequate 
UIC of the placebo group can be attributed to physiological increases in renal iodine 
clearance in pregnancy. Renal iodide clearance does increase in pregnancy, beginning in 
the first trimester with a creatinine clearance increase of as high as 45% by only 9 weeks’ 
gestation.14,31 The effects of renal iodide clearance would likely have been detected in the 
first trimester median UIC values, which were less than 150mcg in both groups. 
Furthermore, in the other studies presented above, non-supplemented groups had 
inadequate median UICs of around 70-80mcg/L in the third trimester despite the same 
changes in renal iodide clearance. In addition to the explanations offered by the study 
authors, it seems likely the baseline iodine sufficiency of the Bangalore subjects elevated 
the median UIC of placebo group as a whole. It is also possible that of the reported 83 
women lost to follow up from the first to the second trimester, more subjects were from 
Bangkok. This would increase the proportion of Bangalore women in the placebo group 
and bring up the value of median UIC. Regardless of the cause, the adequate UIC of the 
Bangalore pregnant population at the time of this study and the iodine sufficiency of the 
placebo group in the second and third trimesters make the outcomes of this study non-
generalizable to areas of true mild to moderate iodine deficiency. Furthermore, the 
sufficient iodine status of the placebo group in the second and third trimesters likely 
positively impacted fetal neurodevelopment. The iodine sufficiency of the placebo group 
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may, therefore, account for the lack of a statistically significant difference in IQ scores 
between groups.  
 
Conclusions from Synthesis of Existing Research 
 
As a whole, this discussion on the relevant literature reveals some avenues for 
future research and improvements for future studies. First, the next trial exploring the 
impact of mild to moderate iodine deficiency on offspring neurodevelopment should be 
an interventional study to comment directly on the recommendations for iodine 
supplementation in pregnancy as recommended by the American and European Thyroid 
Associations. Ideally, this future study would also be designed as a RCT to minimize 
selection bias as may have occurred in the non-randomized control trials outlined above. 
Second, this trial should recruit a sample size that is adequately powered to detect pre-
determined, clinically significant differences between primary outcomes. Third, based on 
the potential shortcomings of the BSID-III, the primary outcome assessment in a future 
trial should reflect long-term neurocognitive outcomes. Fourth, subject recruitment 
should be from a population with documented iodine insufficiency in its population of 
pregnant women. Lastly, this trial should recruit subjects and begin interventional iodine 





CHAPTER 3: PROJECT METHODS 
Project Design  
 
The proposed study will be an interventional, randomized, placebo-controlled, 
double blind trial performed in Southern England. The primary exposure variable will be 
iodine supplementation. Secondary explanatory variables will be thyroid function 
biomarkers during pregnancy and maternal baseline health and socioeconomic 
characteristics. The treatment group will receive a daily oral 150mcg iodine supplement 
from at least 10 weeks’ gestation through pregnancy and the control group will take a 
daily identical placebo pill within the same timeframe. The primary outcome measure of 
this study will be the Wechsler Intelligence Scale for Children (WISC) administered in 
offspring between seven and eight years of age. A secondary outcome measure will be 
BSID-III scores at twelve to eighteen months of age.  
 
Project Population and Sampling  
 
The choice to study the population of pregnant women in Southern England is 
multifactorial but based primarily upon population iodine status. A 2011 national survey 
assessing iodine status in the UK shows an overall mild iodine deficiency. Spot urine 
samples from over 700 schoolgirls aged 14 to 15 years across nine locations in the UK 
found a median UIC of 80.1 mcg/L (IQR: 56.9-109.0).32 More pertinent to the proposed 
study population, a 2014 cross-sectional study of 100 Surrey women in their first 
trimester of pregnancy found a median UIC of 85.3 mcg/L.33 The ALSPAC cohort study 
found a median UIC of 91 mcg/mL in its study sample of 958 pregnant women.4 The 
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median UIC in these studies denote mild iodine deficiency in the overall population and 
iodine insufficiency in pregnant women.   
Despite this insufficiency, the UK lacks a mandatory iodine supplementation 
program, as well as specific recommendations for iodine supplementation in pregnancy. 
Dietary iodine in the UK comes mostly from dairy products secondary to the dairy 
industry’s implementation of iodine disinfectants in the 1930s.34 However, there is no 
national iodine fortification program in the UK nor are there voluntary salt or bread 
iodization programs. Additionally, the most recent UK recommendations for iodine 
intake, published in 1991, do not include recommendations pertaining specifically to 
pregnant women.35 This lack of specific recommendations likely contributes to low 
awareness of the need for iodine supplementation in pregnancy.  A survey of 1,026 
formerly or currently pregnant women between July 2011- February 2012 found that 64% 
had never heard of iodine and 84% did not know that iodine was important for prenatal 
development. Only 30% of these women took an iodine containing supplement 
throughout their pregnancy.36 Given the lack of mandated iodine supplementation and 
pregnancy specific iodine recommendations in this population, designation of a non-
supplemented placebo arm is more plausible than it would be in other populations.   
Additional factors make this population desirable for study. An inherent challenge 
with long-term studies is the potential for loss to follow up. With the UK National Health 
Service, participants’ health records are shared across the system even if they move to 
other regions within the country, aiding in follow up efforts. In addition, this study will 
recruit women in their first trimester. According to National Health Service Data from 
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2017, 61% of UK women saw a healthcare provider about their pregnancy when they 
were 9 weeks pregnant or less, representing a high number of potential subjects for 
recruitment.37 
Pregnant women will be recruited at or within one week of their first antenatal 
visit and must be less than or equal to 10 weeks pregnant as identified by transabdominal 
ultrasound or last menstrual period. Eligible women include those between 18 to 40 years 
of age with a singleton pregnancy. The women must also be generally healthy without 
major medical illness. Women with thyroid disease, taking thyroid medications or taking 
iodine containing supplements will be excluded. Women with TSH levels greater than 
10mIU/L at initial visit will be excluded and referred to an endocrinologist.17  
 Investigators will recruit women from the city of Bristol and surrounding towns 
and from Surrey and surrounding towns with data collection over two years. To detect a 
mean difference of 3.4-points (with a standard deviation of 15) between mean WISC IQ 
scores at an alpha of 0.05 and with 80% power, a total sample of 688 is required. 
Assuming 45% loss to follow up, the aim is to recruit 1,250 pregnant women with a total 
of 625 women in each arm. The ALSPAC cohort study detected a 3.4-point difference in 
mean IQ scores between iodine sufficient and insufficient groups. The proposed study 
will be implemented in the same population. Based on the preliminary data of the 
ALSPAC study, this is a reasonable IQ difference to expect between groups.4 
Additionally, as an increase in one IQ point may yield as much as a 3.631% gain in 
earnings, a 3.4-point IQ difference can have a profound effect on the UK economy.21 
Therefore, detecting this difference between groups would not only be statistically 
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significant but also clinically meaningful. The 45% loss to follow estimation is based 
upon Study 5, which saw a roughly 45% loss to follow up from the time of delivery to 
administration of the WPPSI-III.17 This goal sample size is also sufficient to detect a 4-
point difference with 80% power in BSID-III scores, a secondary outcome measure in 
this study. In past studies, a 4-point difference between groups on the BSID-III has led 
major changes in health campaigns.26  
 
Treatment Groups  
 
Participants will be randomly assigned 1:1 to the interventional or placebo arm 
using a computer-generated sequence and will be stratified by site and gestational age.  
Clinicians and participants will be blinded to treatment. The interventional arm will 
receive a 150 mcg potassium iodide tablet, which is in line with the dose recommended 
by the European Thyroid Association, to take once daily from randomization through 
pregnancy. Subjects assigned to the placebo arm will take a daily placebo tablet, identical 
in color, size and shape, prepared and coded at an outside location. Compliance will be 
assessed via pill count at each trimester of pregnancy and encouraged with phone call 
reminders. All subjects regardless of study arm will be educated about the high iodine 










Project Variables and Measurement Tools  
 
In order to control for secondary explanatory variables in the logistic regression 
model, maternal and fetal health, socioeconomic, sociocultural and thyroid function data 
will be collected (Table 4).  
Table 4. Time Points of Outcome Data Collection.  
Baseline (1st trimester)  UIC, serum TSH, thyroglobulin, FT4 and 
TPO antibody levels, weight, height, 
maternal characteristics questionnaire  
2nd Trimester  UIC, serum TSH, thyroglobulin, FT4 and 
TPO antibody levels, weight, height, side 
effects questionnaire  
3rd Trimester  UIC, serum TSH, thyroglobulin, FT4 and 
TPO antibody levels, weight, height, side 
effects questionnaire 
Delivery Maternal: UIC, serum TSH, thyroglobulin, 
FT4 and TPO antibody levels 
Newborn: sex, gestational age, heel stick 
TSH, APGAR scores, weight, length, head 
circumference  
3-6 months post-partum Maternal: UIC, serum TSH, thyroglobulin, 
FT4 and TPO antibody levels, breast milk 
iodine concentration, parenting 
questionnaire  
Offspring at 12-18 months Maternal: parenting questionnaire  
Child: weight, height, head circumference, 
UIC, heel prick TSH, BSID-III 
Offspring at 7-8 years old  Maternal: parenting questionnaire  
Child: weight, height, UIC, finger-prick 
TSH, WISC 
 
At baseline, recruited subjects will complete a structured multiple-choice questionnaire 
assessing maternal education level, relationship status, paternal education level, 
household income, use of nutritional supplements, thyroid disease and diet. Venipuncture 
blood sample will be collected in all three trimesters, at delivery and at 3 to 6 months 
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postpartum to obtain maternal UIC, TSH, thyroglobulin, FT4 and TPO antibody levels. 
UIC will be measured using ThermoElemental X-Series Quadrupole Inductively Coupled 
Plasma Mass Spectrometer against internal standards.34 Thyroid function tests will be 
measured by immunoassay with the IMMULIT, Siemens Healthcare Diagnostics using 
the manufacturer’s reference ranges.17 Infant development will be measured using the 
Bayley Scale of Infant Development (BSID-III), a commonly used tool to measure 
cognitive and motor development in children aged 1-42 months old. The BSID-III 
measures two developmental indices, psychomotor (PDI) and mental (MDI). The 
standardization sample of BSID-III scoring is based on the scores of 1,700 children in the 
United States. Composite scores range from 40 to 160 with a mean score of 100 and a 
standard deviation of 15.38,39 IQ will be measured using the Wechsler Intelligence Scale 
for Children (WISC), a commonly used assessment to calculate full scale IQ in children 
from 6 to 16 years old.40  
The fifth edition is the newest version of the WISC and has ten primary subtests. 
Seven of these subtests, including vocabulary, matrix reasoning and coding, contribute to 
the full-scale IQ score. In order to test distinct cognitive domains, three additional 
primary subtests, visual puzzles, picture span and symbol search, contribute to five factor 
index scores: Verbal Comprehension, Visual Spatial, Fluid Reasoning, Working Memory 
and Processing Speed. The standardization sample is based on the scores of 2,200 
American children. Full scale IQ scores range from 69 to 130 with a mean score of 100 






Information about this project will be disseminated by posting flyers in women’s 
health clinic waiting rooms, local hospitals and preschools in Surrey and Bristol. 
Interested women may request additional information by contacting the study coordinator 
via email or telephone. Information sessions will also be held at the major hospitals and 
antenatal clinics in Surrey and Bristol to educate practitioners about this project and 
about the increased iodine requirements in pregnancy. Midwives, obstetricians and 
general practitioners will be able to refer patients at their first antenatal visit for 
participation in this study. All women who consent to the study and meet the inclusion 
criteria will be given written informed consent and will continue seeing their obstetrician. 
Following delivery, annual birthday cards to study offspring and newsletter updates will 





 Clinical researcher assistants will be posted at the major hospitals and associated 
antenatal clinics in Surrey and Bristol. At an initial meeting with a clinical research 
assistant on the day of or within one week of the first antenatal visit, subjects will 
complete the structured baseline characteristics questionnaire using survey software on a 
portable tablet. At this visit, spot urine and venipuncture samples will also be collected. 
Recruited women will have similar visits with clinical research assistants in the 2nd and 
3rd trimesters and postpartum, when spot urine and venipuncture samples will be 
 
43 
collected. After delivery, data will be collected from the electronic health record 
regarding infant birth outcomes, including method of delivery, gestational age at delivery, 
APGAR scores, height, weight, head circumference and heel prick TSH. Trained masters 
level psychologists will administer and score the BSID-III when offspring are between 
twelve and eighteen months of age at the participants’ homes.  Trained study personnel 
will administer the WISC at the participants’ homes when offspring are between the ages 
of 7 and 8 years old.  
 Research staff will store all collected data from baseline through WISC 
administration in a comprehensive excel spreadsheet. This spreadsheet will be encrypted 




Continuous variables, including BMI, UIC, TSH, thyroglobulin, FT4 and 
birthweight, will be reported using mean and standard deviation or median and range as 
appropriate. Data will be compared between groups using two-sample t-tests. Categorical 
data, including TPO antibody positivity, maternal and paternal education (broken down 
by highest earned degree level: no degree, secondary school, university, master’s and 
doctoral), relationship status, income status (broken down by tertile) and offspring sex, 
will be presented as number of participants in each category and proportion of the total 
group. Data will be compared between the two groups using two-proportion z-tests. UIC 
will also be compared within and between each group from baseline concentration to 
second and third trimester using a two-way repeated measures ANOVA.    
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For the WISC, six mean scores and standard deviations will be reported for both 
the iodine and control group including full scale IQ, Verbal Comprehension score, Visual 
Spatial score, Fluid Reasoning score, Working Memory score and Processing speed 
score. The scores will be compared using a logistic regression model with the treatment 
variable, household income, maternal education, offspring birthweight, age and sex as 
inputs to control for differences between groups.42 Secondary outcomes measures such as 
BSID-III scores will be similarly analyzed using a logistic regression model with the 
same explanatory variable inputs.  
 
Timeline and Resources  
  
Before initiating this study, roughly 12 months will be allotted for IRB approval, 
recruitment of staff, education of local obstetricians and practitioners and logistical 
planning. Recruitment for the study will begin in the winter of 2020. Recruitment and 
data collection (including baseline maternal data, second and third trimester laboratory 
data and neonatal laboratory data) will take place over the course of two years and is 
expected to be completed by winter of 2022. According to the United Kingdom Statistics 
Authority estimations of 2016 live births, there were a total of 19,823 live births in these 
two areas in one year.43 Based on this data and the fact that the majority of UK women 
present before nine weeks gestation, two years duration is a reasonable timeframe to 
recruit 1,250 pregnant women.37 Iodine supplementation will occur from time of 
enrollment through parturition. WISC scores will be collected over a three-year span 
from 2027 though 2030. Final data collection will take place in 2030 with conclusion of 
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the study. The entire study will take roughly 10 years to complete. An additional six 
months to one year will be required for data analysis and manuscript.  
 The study will require a large team. There will be a primary and co-investigator 
responsible for oversight of the entire project over the course of 10 years. They will also 
oversee a team of clinical research assistants. The team of roughly six clinical research 
assistants will be essential in the data collection process during the first phase of the 
study. They will obtain informed consent from new subjects, administer the baseline 
questionnaire and oversee laboratory data collection. They will also be responsible for 
recording the data of their recruited subjects in the encrypted spreadsheet. The research 
assistants will be posted at the major antenatal and maternity services hospitals in the 
Bristol and Surrey areas (Royal Surrey County Hospital, St. Peter’s Hospital, East Surrey 
Hospital, Bristol Royal Infirmary and University Hospitals Bristol). A team of 
endocrinologists will interpret thyroid function test lab data.  
A study coordinator will organize information sessions for providers at local hospitals 
and keep track of study participants over the ten-year period. In the second phase of the 
study, the study coordinator will organize and deploy a team of master’s level 
psychologists to administer the BSID-III and trained study personnel to administer the 
WISC at the participants’ homes. A statistician will be required at the end of the first 
two-year period in 2022 for preliminary data analysis and at the conclusion of the study 
in 2030 for final data analysis. 
While the subjects’ clinicians will not technically function as part of the research 
team, each participating subject should continue to see their obstetrician and/or midwife 
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at the providers’ discretion. Obstetricians and midwives may direct any questions or 
concerns regarding their patients’ enrollment in the study toward their on-site clinical 
research assistant.  
 Specialty laboratory analysis will be required. Spot urine samples will be sent to 
the Trace Element Laboratory at the University of Surrey for UIC measurement via mass 
spectrometry.34 Thyroid function markers, thyroglobulin and TPO antibodies will be 
measured using immunoassays at the Royal Surrey County Hospital laboratory for Surrey 
subjects and University Hospitals Bristol laboratory for the Bristol subjects.  
 
Institutional Review Board 
This study employs an intervention that poses minimal risk to the fetus with the 
prospect of direct benefit for offspring. There is a risk of privacy breach as well as 
discomfort and bleeding from venipuncture. Given the fact that study participants will be 
pregnant women at the time of recruitment and children at the time of primary outcome 
assessment, the subjects are a protected population. As such, this study will require an 
IRB application for full-board review.44 Participants will be consented for all study 















 The proposed study design has some limitations. The study’s ten-year timeframe 
will make it difficult to track the whereabouts of all study participants for final outcome 
assessment. The 45% loss to follow up rate proposed in this study is based upon the 
roughly 45% final loss to follow up rate in Study 5.17 Study 5 implemented its final 
outcome assessment when offspring were 5.4 years old on average, while this study will 
administer the WISC when children are 7 to 8 years old. In this study, the longer period 
from parturition to final outcome assessment may yield greater than a 45% loss to follow 
up rate, resulting in an inadequately powered study. However, the proposed 45% loss to 
follow up rate is felt to be reasonable in this population given the presence of the 
National Healthcare System which will ease in locating study subjects. An additional 
drawback of the extended time period is that over the course of seven to eight years, 
multiple environmental, nutritional, educational and sociocultural exposures will impact 
the IQ of offspring. Assuming that these factors are distributed evenly between the two 
groups, they would theoretically bias the study results to find no effect. The extended 
time frame will also make the study expensive. 
This study’s weaknesses are accompanied by quite a few strengths. The first 
strength lies in its design; this study is a randomized, placebo-controlled interventional 
study that aims to recruit a large sample size. In its interventional design, the results of 
this study will comment directly on the recommendations of the European Thyroid 
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Association. This study also selects an appropriate population for study. The baseline 
iodine deficiency in the UK will make the results of this study generalizable to other 
iodine insufficient populations. Furthermore, the lack of iodine supplementation 
programs and iodine specific recommendations for pregnant women in the UK make this 
study ethically plausible. This study will also only include women presenting within ten 
weeks’ gestation. Iodine supplementation in the first months of pregnancy is likely the 
most impactful on fetal neurodevelopment and, thus, this study is more likely to detect an 
effect from supplementation. The final strength of this study lies in its primary outcome 
assessment. The WISC will assess a wide range of cognitive functions and reflects long-
term neurocognitive outcomes.  
An anticipated obstacle is achieving adequate power given the potential for high 
loss to follow up rates and getting funding given the ethical implications of withholding 
iodine supplementation from the control group. This population was specifically selected 
to overcome this ethical dilemma because the UK lacks recommendations for iodine 
supplementation pertaining to pregnant women and iodine supplementation programs. 
Furthermore, participants will be educated about iodine-rich foods and encouraged to 
incorporate these foods into their diets. Nevertheless, and as displayed in the synthesis of 
existing research section, it is possible that the study may be prematurely aborted for 
ethical reasons given the international recommendations for iodine supplementation in 
pregnancy.  It is also possible that over the course of the recruitment period, the policy 
within England may change to favor supplementation. If this were to occur, pregnant 
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 Over the past 100 years, there has been great progress in iodine supplementation 
efforts. The recognition that iodine supplementation in pregnancy can eradicate cretinism 
along with the implementation of iodine supplementation programs in many countries 
displays this progress. However, there are still a number of countries with iodine 
insufficient populations. The unique physiology of pregnancy and increased thyroid 
hormone requirement makes pregnant women more prone to iodine deficiency. Iodine 
deficiency may have adverse effects on the developing fetus. This is a preventable 
problem that has been addressed by the European and American Thyroid Associations, 
which call for iodine supplementation in pregnancy in mildly to moderately deficient 
populations.   
There is data indicating that iodine sufficiency (UIC >150mcg/L) and/or iodine 
supplementation in pregnancy has a clinically meaningful impact on offspring 
neurocognitive development. However, other studies have found no association between 
iodine sufficiency/supplementation and neurocognitive benefit. The proposed study has 
drawn upon these studies and intends to contribute to this body of conflicting data. 
Furthermore, this study was designed to overcome the shortcomings of the existing data 
by beginning supplementation in the first trimester, selecting an appropriately deficient 




Clinical and Public Health Significance 
 
 If the proposed study does detect clinically meaningful change, it will likely have 
significant public health implications for this population.  Given that the minority of 
pregnant women take prenatal iodine-containing supplements, this study may prompt an 
increase in the percentage of women taking iodine supplements during pregnancy. 
Increased supplementation may come secondary to increased recommendations from 
healthcare providers or it may come from increased inclusion of iodine in prenatal 
vitamins. This study will not only contribute to the literature documenting the iodine 
insufficient status of the UK but it may also illustrate how iodine supplementation can 
lead to meaningful change. Results from studies like this are needed to initiate 
discussions and perhaps actions around salt or bread iodization efforts in the UK. If 
offspring of supplemented pregnancies do see a 3.4-point increase in IQ, the individual 
subjects along with this region in Southern England will reap the expected significant 
economic benefit that comes with increased IQ score. Finally, a study such as this will 
likely prompt future studies in other iodine insufficient populations and, perhaps, 
research into the neurocognitive impact of iodine supplementation specifically during 
lactation.  Consequently, the results of this study may bolster the European and American 
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